Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER

One-third of patients with high-risk prostate cancer referred for curative-intent radiotherapy were upstaged on PSMA PET/CT. This finding supports the use of PSMA PET/CT for staging, especially in patients with multiple high-risk features, and suggests a need for treatment adaptations accordingly, which will be further investigated in the THUNDER trial.

Authors

Institutions

Publication Details

Journal
European Urology Oncology
Published
2025-09-25
DOI
https://doi.org/10.1016/j.euo.2025.08.005
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER

Maréva Lamande, Guillaume Grisay, Nicolas Jullian, Filip Poelaert et al.
European Urology Oncology
Prostate Cancer Treatment and Research
article

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER

Maréva Lamande, Guillaume Grisay, Nicolas Jullian, Filip Poelaert, Michiel Strijbos, Karolien Goffin, Nadia Withofs, Samuel Bral, Valérie Fonteyne, Fleur Kleiburg, Piet R. Dirix, Sabine Meersschout, Jolien Verschueren, Brieuc Sautois, Nick Liefhooghe, Piet Ost, Bart De Troyer, Ad Vandermeulen, Lorenzo Staelens
article en

Abstract

One-third of patients with high-risk prostate cancer referred for curative-intent radiotherapy were upstaged on PSMA PET/CT. This finding supports the use of PSMA PET/CT for staging, especially in patients with multiple high-risk features, and suggests a need for treatment adaptations accordingly, which will be further investigated in the THUNDER trial.

European Urology OncologyVol. 8(5)
Cliniques Universitaires Saint-Luc (BE), Leiden University Medical Center (NL), Universitair Ziekenhuis Leuven (BE), AZ Groeninge (BE), Ghent University Hospital (BE), Institut Jules Bordet (BE), Antwerp Management School (BE), Onze Lieve Vrouwziekenhuis Hospital (BE), Province of Antwerp (BE), AZ Sint-Jan (BE), Vlaamse Vereniging voor Obstetrie en Gynaecolo (BE), Centre Hospitalier Universitaire de Liège (BE), Iridium Kankernetwerk (BE), AZ Delta (BE), Flanders Environment Agency (BE)
Openalex Percentile: Top 62%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.